AFMD - Affimed inks clinical pact with NKMax America for solid tumors

Affimed ([[AFMD]] -2.2%) and NKMax America have entered into a clinical collaboration agreement to investigate the combination of former's AFM24 with later's autologous NK cell product SNK01.The companies plan to explore the combination in a first-in-human proof-of-concept trial in patients with EGFR-expressing tumors, to establish safety and recommended dose.Under the agreement, the companies will contribute their respective product candidates and resources towards submitting an Investigational New Drug application to the FDA.The clinical trial will combine SNK01 with AFM24 in the autologous setting with the option to expand the clinical trial to the allogeneic setting. The cost of the clinical study will be shared by Affimed and NKMax America.AFM24, a tetravalent, bispecific epidermal growth factor receptor ((EGFR))- and CD16A-binding ICE, activates innate immunity to kill solid tumors, inducing both antibody-dependent cellular cytotoxicity and antibody-dependent cellular phagocytosis.First-in-human Phase 1/2a multiple ascending dose escalation/expansion study is underway evaluating AFM24 as monotherapy in patients with

For further details see:

Affimed inks clinical pact with NKMax America for solid tumors